title: [Diagnostics and treatment of polyglandular syndrome of adults].
abstract: Autoimmune polyendocrine syndromes (APS) are rare endocrinopathies characterized by the coexistence of at least two glandular autoimmune diseases. APS comprise a wide spectrum of autoimmune disorders and are divided into a very rare juvenile (APS type 1) and a more common adult type with (APS 2) or without adrenal failure (APS 3). The first clinical manifestations of APS 1 usually occur in childhood whereas APS 2 mostly occurs during the third and fourth decades of life. The third type has been described in adults that, contrary to types 1 and 2, does not involve the adrenal cortex. No clinical differences between types 2 and 3 have been described except the absence of adrenal failure. Type 4 APS is a rare syndrome characterized by the combination of autoimmune conditions not falling into the above categories. It consists of adrenal failure with one or more minor autoimmune disorders barring major components of type 1 and 2 APS. Usually, autoimmune polyendocrine syndrome of adults manifests itself as one of the major autoimmune diseases (such as adrenal failure, Grave's disease, or type 1 diabetes) and minor autoimmune disorders (vitiligo, alopecia) preceding the development of autoimmune deficiency of major endocrine glands. This article describes a patient with type 3 APS, who developed type 1 diabetes. Grave's disease and vitiligo. The development of the syndrome started from vitiligo in the chidhood. Moreover, the patient suffered primary sterility and presented with progressive diabetic nephropathy of autoimmune origin. It is concluded that patients with a single autoimmune component of polyendocrine syndrome should be screened to exclude other autoimmune endocrine disorders.
authors.forename: A A
authors.initials: AA
authors.lastname: Larina
authors.forename: O S
authors.initials: OS
authors.lastname: Shapoval'iants
authors.forename: N V
authors.initials: NV
authors.lastname: Mazurina
authors.forename: E A
authors.initials: EA
authors.lastname: Troshina
mesh_terms: D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000503:physiopathology; D006058:Gonadal Disorders / Q000209:etiology* / Q000503:physiopathology; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008297:Male; D008991:Monitoring, Physiologic; D016884:Polyendocrinopathies, Autoimmune / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D012074:Remission Induction; D013963:Thyroid Hormones / Q000008:administration & dosage; D013965:Thyroidectomy / Q000379:methods; D013971:Thyrotoxicosis / Q000209:etiology* / Q000503:physiopathology / Q000601:surgery; D014820:Vitiligo / Q000209:etiology*
chemical_list: D007004:Hypoglycemic Agents; D013963:Thyroid Hormones